Form 8-K - Current report:
SEC Accession No. 0001193125-25-120824
Filing Date
2025-05-15
Accepted
2025-05-15 16:18:26
Documents
15
Period of Report
2025-05-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d889805d8k.htm   iXBRL 8-K 26010
2 EX-99.1 d889805dex991.htm EX-99.1 90853
6 GRAPHIC g889805dsp00.jpg GRAPHIC 2507
  Complete submission text file 0001193125-25-120824.txt   253926

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rntx-20250515.xsd EX-101.SCH 2857
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rntx-20250515_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rntx-20250515_pre.xml EX-101.PRE 11266
18 EXTRACTED XBRL INSTANCE DOCUMENT d889805d8k_htm.xml XML 3678
Mailing Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758
Business Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758 7378021989
Rein Therapeutics, Inc. (Filer) CIK: 0001420565 (see all company filings)

EIN.: 134196017 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38130 | Film No.: 25953566
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)